Gamida Cell Ltd. Skyrocketed
Gamida Cell Ltd. (GMDA:NASDAQ) jumped higher at $2.72, a gain of 22.5%. On Tue, Jan 18, 2022, GMDA:NASDAQ touched a New 2-Week Low of $2.22. The stock got featured on our News Catalysts scanner on Wed, Jan 19, 2022 at 07:29 AM in the 'INVESTOR UPDATE' category. From Wed, Jan 05, 2022, the stock recorded 25.00% Up Days and 22.22% Green Days
The stock spiked on Tue, Dec 28, 2021 at $3.38 with a volume of 6M+, and its share price has been moving sideways in recent weeks.
About Gamida Cell Ltd. (GMDA:NASDAQ)
Gamida Cell Ltd is engaged in the development of cellular and immune therapeutics for cancer and rare genetic diseases. The company's lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy for use as a curative stem cell graft for patients in hematopoietic stem cell transplant. It is also developing NAM-NK, an innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma.
Top 10 Gainers:
- Zogenix, Inc. (ZGNX:NASDAQ), 65.73%
- G Medical Innovations Holdings Ltd. (GMVD:NASDAQ), 45.37%
- Valneva SE (VALN:NASDAQ), 45.01%
- Vivos Therapeutics Inc. (VVOS:NASDAQ), 41.1%
- ShiftPixy, Inc. (PIXY:NASDAQ), 31.5%
- Evofem Biosciences, Inc. (EVFM:NASDAQ), 22.86%
- Gamida Cell Ltd. (GMDA:NASDAQ), 22.52%
- ReTo Eco-Solutions, Inc. (RETO:NASDAQ), 22.03%
- Muscle Maker, Inc. (GRIL:NASDAQ), 21.64%
- Platinum Group Metals Ltd. (PLG:NYSEMKT), 20.73%